PDF Cover

Mosunetuzumab Market

The market for Mosunetuzumab was estimated at $361 million in 2024; it is anticipated to increase to $550 million by 2030, with projections indicating growth to around $783 million by 2035.

Report ID:DS1802369
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Mosunetuzumab
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Mosunetuzumab Market Outlook

Revenue, 2024

$361M

Forecast, 2034

$729M

CAGR, 2025 - 2034

7.3%

The Mosunetuzumab industry revenue is expected to be around $387.0 million in 2025 and expected to showcase growth with 7.3% CAGR between 2025 and 2034. The significant growth in the Mosunetuzumab market highlights its importance and relevance within the field of biopharmaceuticals industry as a crucial treatment option for serious diseases like cancer being driven by advancements in biotechnology and increasing patient awareness and demand for precise biological therapies in oncology field globally along with rising cancer cases worldwide and proven effectiveness of Mosunetuzumab in various clinical studies further boosts its relevance, in the market.

Mosunetuzumab, also known as Lunsumio, is like a kind of antibody that can interact with two different targets at the same time. CD3 on T cells and CD20 on B cells Its made to help T cells target and eliminate cancerous B cells effectively in patients with Non Hogkins Lymphoma This unique ability marks a significant advancement, in treating blood cancers like never before Mosunetuzumab is truly shaping the future of medicine in fighting hematologic malignancies.

Mosunetuzumab market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Mosunetuzumab Market Outlook

Market Key Insights

  • The Mosunetuzumab market is projected to grow from $360.7 million in 2024 to $730 million in 2034. This represents a CAGR of 7.3%, reflecting rising demand across Oncology Hospitals, Cancer Research Institutes, and Specialty Clinics.

  • This is a highly consolidated market with 2 key players, where Genentech Inc. holds the dominant share.

  • U.S. and UK are the top markets within the Mosunetuzumab market and are expected to observe the growth CAGR of 4.7% to 7.0% between 2024 and 2030.

  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 8.4% to 10.1%.

  • Slow adoption of Advancements in Immunotherapy transition within key players in Mosunetuzumab market is creating a revenue window for adjacent and alternate markets like Rituximab and Brentuximab Vedotin to improve its use-case penetration in Oncology Hospitals and Cancer Research Institutes applications and expected to capture $25 million revenue from existing Mosunetuzumab market.

  • The Mosunetuzumab market is set to add $369 million between 2024 and 2034, with manufacturer targeting Cancer Research Institutes & Specialty Clinics Application projected to gain a larger market share.

  • With

    increasing prevalence of non-hodgkin lymphoma, and

    Provocative research and clinical trials, Mosunetuzumab market to expand 102% between 2024 and 2034.

mosunetuzumab market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Mosunetuzumab - Country Share Analysis

Opportunities in the Mosunetuzumab

The potential for treating blood cancer with Mosunetuzumab is also significant. has the opportunity to reach a wider market with its expansion into new clinical applications beyond its current use case. Conducting studies on its impact, on different cancers could lead to a more diverse product range and greater commercial achievements.

Growth Opportunities in North America and Europe

The American region has experienced a growing fascination with Mosunetuzumab due to significant progress in cancer research in the United States and Canada specifically for treating non Hodgkins lymphoma. This rise is fueled by increased investments in research and development projects along with a rise in healthcare spending and heightened patient knowledge. Nonetheless competing companies, like Genentech are intensifying competition in this sector with their presence. The promising regulatory environment and growing acceptance of healthcare will provide ongoing strong prospects.
In Europe's oncology research landscape in countries like Germany, Austria and the UK Mosunetuzumab is gaining attention for its potential in targeted immunotherapies for lymphomas due to increased funding. Its importance is underscored by the rising number of individuals affected by such diseases. Despite facing competition, from known monoclonal antibodies Mosunetuzumabs distinct approach and positive trial results showcase its promise. Moreover efforts, from the European Medical Agency to speed up the approval of cancer treatments offer promising chances for the market to grow in the region.

Market Dynamics and Supply Chain

01

Driver: Expanding Bispecific Antibody Adoption and Rising Demand for Targeted Immuno-Oncology Therapies

The expanding adoption of bispecific antibody therapies is also a core growth factor driving demand for mosunetuzumab. Bispecific antibodies engage two targets simultaneously, enhancing immune cell recruitment against cancer cells. This targeted mechanism has also resonated with oncology specialists seeking more precise treatments that improve response rates while managing safety profiles. Alongside this, there is also a rising demand within immuno-oncology for therapies that can also address relapsed or refractory lymphomas where traditional monoclonal antibodies and chemotherapies fall short. Clinicians increasingly favor agents that harness the patient’s own T cells to eliminate tumor cells, positioning mosunetuzumab’s CD20 x CD3 bispecific design as a preferred choice. Together, these industry trends fuel portfolio diversification at cancer centers and support broader inclusion of bispecifics in treatment guidelines, ultimately enhancing clinical adoption and revenue generation in niche hematologic oncology markets.
A key market driver for mosunetuzumab is also the increased industry focus on outpatient cancer care and treatment convenience. Healthcare providers and patients alike are also seeking effective therapies that can also be administered safely in outpatient or specialty clinic settings, reducing the need for prolonged hospital stays. Mosunetuzumab’s manageable infusion profile and supportive safety monitoring make it suitable for delivery outside of intensive inpatient units. This trend aligns with broader shifts toward ambulatory oncology services, where convenience, reduced healthcare costs, and improved quality of life are also prioritized. As outpatient infusion capacity expands and clinician experience with bispecifics grows, mosunetuzumab benefits from heightened demand within community oncology practices and specialty clinics focused on delivering advanced biologic therapies efficiently and patient-centrically.
02

Restraint: Complex Safety Monitoring Requirements and Immune-Related Adverse Events Limit Wider Adoption

Mosunetuzumab’s T-cell engaging mechanism introduces safety challenges that act as a market restraint. Risks such as cytokine release syndrome and neurotoxicity require step-up dosing, close monitoring, and experienced clinical teams. This limits use to well-equipped oncology hospitals and delays adoption in smaller specialty clinics. For example, centers without intensive monitoring infrastructure may avoid prescribing it, reducing patient reach and slowing demand growth. These requirements also increase treatment costs and operational burden, which can affect reimbursement decisions. As a result, revenue generation remains concentrated in select institutions, constraining broader market penetration and influencing cautious prescribing behavior.
03

Opportunity: Strategic Partnerships and Collaborations and Investing in Technological Advancements

In a field where teamworks crucially important working together with universities, research centers and other pharmaceutical companies could speed up the development of the Mosunetuzumab research. By building these connections There is a chance, for exchanging ideas and resources well as attracting additional funding, which could boost the success of Mosunetuzumab in the worldwide pharmaceutical industry.
Advancements in technology within the field could boost the efficiency and expansion of the manufacturing process for Mosunetuzumab drug production. Breakthroughs in biotechnology have significantly progressed the creation of cancer treatment medications; keeping up with these advancements may enhance the effectiveness of Mosunetuzumab and its competitive edge, in the market.
04

Challenge: Strong Competition from CAR-T Therapies and Emerging Bispecific Antibodies Pressure Demand

Intense competition from CAR-T cell therapies and next-generation bispecific antibodies is another major restraint for mosunetuzumab. CAR-T treatments, despite higher costs, offer durable responses that attract eligible patients and clinicians. At the same time, newer bispecific antibodies with differentiated dosing schedules or safety profiles are entering clinical practice. For instance, physicians may prefer alternative CD20 x CD3 agents perceived to have simpler administration or stronger efficacy data. This competitive landscape fragments demand, limits pricing flexibility, and challenges long-term revenue growth. Consequently, mosunetuzumab must compete aggressively for guideline inclusion and physician preference within a crowded immuno-oncology market.

Supply Chain Landscape

1

Raw Materials Sourcing

Lonza GroupWuXi Biologics
2

API Production

Genentech Inc.Lonza Group
3

Formulation & Fill Finish

Thermo Fisher ScientificCatalent Inc.
4

End Users & Applications

Oncology HospitalsCancer Research Institutes
Mosunetuzumab - Supply Chain

Use Cases of Mosunetuzumab in Oncology Hospitals & Cancer Research Institutes

Oncology Hospitals : In oncology hospitals, mosunetuzumab is primarily used as a bispecific CD20 x CD3 antibody therapy administered through intravenous infusion for patients with relapsed or refractory B cell lymphomas. These hospitals are the main end users due to their advanced infusion infrastructure, multidisciplinary oncology teams, and capability to manage immune related adverse events. The key advantage of mosunetuzumab in this setting is its off the shelf availability compared to personalized cell therapies, enabling faster treatment initiation. Oncology hospitals benefit from its targeted immune activation, which allows effective tumor cell killing while maintaining controlled dosing and monitoring in inpatient or outpatient hospital environments.
Cancer Research Institutes : Cancer research institutes utilize mosunetuzumab mainly within clinical trials and translational research programs to explore its broader therapeutic potential. In this application, the drug is used in its investigational and clinical grade form to study efficacy across different B cell malignancies and treatment lines. Research institutes focus on optimizing dosing schedules, combination strategies, and biomarker driven patient selection. A unique advantage in this segment is the ability of mosunetuzumab to provide insights into T cell engaging therapies without the complexity of cell manufacturing. This supports innovation in immuno oncology research and accelerates development of next generation bispecific antibody platforms.
Specialty Clinics : In specialty clinics, particularly hematology and oncology focused centers, mosunetuzumab is increasingly adopted for outpatient management of eligible lymphoma patients. The therapy is commonly administered as scheduled intravenous infusions under specialist supervision. These clinics value mosunetuzumab for its manageable safety profile and reduced logistical burden compared to intensive hospital based treatments. Its targeted mechanism enables effective disease control while supporting continuity of care closer to the patient’s home. Specialty clinics benefit from improved patient convenience, reduced hospitalization needs, and the ability to integrate advanced biologic therapies into routine practice for relapsed or refractory cancer populations.

Recent Developments

Recent strategic developments for Lunsumio highlight its expanding role as a CD20 x CD3 bispecific antibody in treating relapsed or refractory B-cell lymphomas. Ongoing clinical data continue to support improved response rates, fueling interest from oncology specialists and inclusion in emerging immuno-oncology treatment algorithms. A key market trend is the integration of personalized medicine, where biomarker-guided therapies and precision dosing enhance patient outcomes. This trend aligns with broader shifts toward targeted biologics, optimized cancer immunotherapy, and outpatient infusion protocols that improve convenience and cost efficiency.

September 2025 : Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of a subcutaneous formulation of Lunsumio for adults with relapsed or refractory follicular lymphoma after at least two systemic therapies. This development signals broader EU market entry and potential increased demand due to easier, injection-based administration compared to intravenous infusion.
March 2025 : Chugai Pharmaceutical launched LUNSUMIO in Japan for relapsed or refractory follicular lymphoma, following regulatory approval by Japan’s Ministry of Health, Labour and Welfare and inclusion on the national health insurance price list. This launch expands commercial reach in the Asia Pacific region, enabling patient access under reimbursement coverage.

Impact of Industry Transitions on the Mosunetuzumab Market

As a core segment of the Pharmaceutical industry, the Mosunetuzumab market develops in line with broader industry shifts. Over recent years, transitions such as Advancements in Immunotherapy and Focus on Personalized Medicine have redefined priorities across the Pharmaceutical sector, influencing how the Mosunetuzumab market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Advancements in Immunotherapy

The biopharmaceutical sector has experienced changes in the past years due to advancements in areas such as immunotherapy. The emergence of treatments like Mosunetuzumab, a dual purpose antibody is transforming the way conditions like lymphoma and leukemia are treated. By being an addition to the arsenal used against cancers, the creation and use of Mosunetuzumab demonstrate the impact of pioneering breakthroughs, in immunotherapy influencing not only just patient results but also shaping trends within the industry.
02

Focus on Personalized Medicine

The growing focus on personalized medicine represents a major industry transition shaping the development and adoption of mosunetuzumab. As a targeted CD20 x CD3 bispecific antibody, mosunetuzumab enables treatment strategies tailored to individual disease biology and patient response profiles. This shift has influenced healthcare delivery by increasing reliance on biomarker testing, patient stratification, and customized dosing approaches in oncology practice. Pharmaceutical companies are investing more heavily in precision biologics and companion diagnostics to support individualized therapies. The biotechnology sector is also advancing antibody engineering platforms to enhance specificity and safety. Together, these changes are redefining cancer care models, improving clinical outcomes, and driving innovation across the personalized therapeutics ecosystem.